Weigao II

completed

Weigao and its subsidiaries (together “the Group”) is the leading manufacturer of single-use medical devices in China. The Group has a wide range of products, which includes: (a) consumables (infusion set, syringes, medical needle, blood bags, pre-filled syringes, blood sampling products, and other consumables); (b) orthopedic materials (such as steel plates and screws); and (c) blood purification consumables (such as dialysis equipment). Weigao is listed on the Hong Kong Stock Exchange.The blood purification business is based in one of Weigao’s subsidiaries – Weigao Blood. Weigao Blood covers a wide range of blood purification medical devices including hemodialysis machines, high and low flux polysulfone membrane dialyzers and tubing system. In addition to manufacturing, Weigao blood also has a healthcare holding company known as Shandong Weigao Medical Holding Company Limited which runs hemodialysis centers. All the dialysis centers have facilities where patients receive treatment for about 4 hours twice or thrice a week. No patients stay overnight at these centers. The proposed IFC investment is a debt investment (A loan), proceeds of which will be used towards financing the expansion of Weigao’s blood purification business under its subsidiary, Weigao Blood, through: (i) the expansion of its manufacturing capacity for dialyzer, tubing and related consumables; and (ii) the opening additional company-operated standalone dialysis centers (together, the “Project”).  The expected size of the dialysis centers would be between 10 to 100 treatment beds.